Standard
Simultaneous Onset of Haematological Malignancy and COVID : An Epicovideha Survey. / Cattaneo, Chiara; Salmanton-García, Jon; Marchesi, Francesco; El-Ashwah, Shaimaa; Itri, Federico; Weinbergerová, Barbora; Gomes Da Silva, Maria; Dargenio, Michelina; Dávila-Valls, Julio; Martín-Pérez, Sonia; Farina, Francesca; Van Doesum, Jaap; Valković, Toni; Besson, Caroline; Poulsen, Christian Bjørn; López-García, Alberto; Žák, Pavel; Schönlein, Martin; Piukovics, Klára; Jaksic, Ozren; Cabirta, Alba; Ali, Natasha; Sili, Uluhan; Fracchiolla, Nicola; Dragonetti, Giulia; Adžić-Vukičević, Tatjana; Marchetti, Monia; Machado, Marina; Glenthøj, Andreas; Finizio, Olimpia; Demirkan, Fatih; Blennow, Ola; Tisi, Maria Chiara; Omrani, Ali S.; Navrátil, Milan; Ráčil, Zdeněk; Novák, Jan; Magliano, Gabriele; Jiménez, Moraima; Garcia-Vidal, Carolina; Erben, Nurettin; Del Principe, Maria Ilaria; Buquicchio, Caterina; Bergantim, Rui; Batinić, Josip; Al-Khabori, Murtadha; Verga, Luisa; Szotkowski, Tomáš; Samarkos, Michail; Ormazabal-Vélez, Irati; Meers, Stef; Maertens, Johan; Pinczés, László Imre; Hoenigl, Martin; Drgoňa, Ľuboš; Cuccaro, Annarosa; Bilgin, Yavuz M.; Aujayeb, Avinash; Rahimli, Laman; Gräfe, Stefanie; Sciumè, Mariarita; Mladenović, Miloš; Çolak, Gökçe Melis; Sacchi, Maria Vittoria; Nordlander, Anna; Berg Venemyr, Caroline; Hanáková, Michaela; García-Poutón, Nicole; Emarah, Ziad; Zambrotta, Giovanni Paolo Maria; Nunes Rodrigues, Raquel; Cordoba, Raul; Méndez, Gustavo Adolfo; Biernat, Monika M.; Cornely, Oliver A.; Pagano, Livio.
In:
Cancers, Vol. 14, No. 22, 5530, 2022.
Research output: Contribution to journal › Journal article › Research › peer-review
Harvard
Cattaneo, C, Salmanton-García, J, Marchesi, F, El-Ashwah, S, Itri, F, Weinbergerová, B, Gomes Da Silva, M, Dargenio, M, Dávila-Valls, J, Martín-Pérez, S, Farina, F, Van Doesum, J, Valković, T, Besson, C
, Poulsen, CB, López-García, A, Žák, P, Schönlein, M, Piukovics, K, Jaksic, O, Cabirta, A, Ali, N, Sili, U, Fracchiolla, N, Dragonetti, G, Adžić-Vukičević, T, Marchetti, M, Machado, M
, Glenthøj, A, Finizio, O, Demirkan, F, Blennow, O, Tisi, MC, Omrani, AS, Navrátil, M, Ráčil, Z, Novák, J, Magliano, G, Jiménez, M, Garcia-Vidal, C, Erben, N, Del Principe, MI, Buquicchio, C, Bergantim, R, Batinić, J, Al-Khabori, M, Verga, L, Szotkowski, T, Samarkos, M, Ormazabal-Vélez, I, Meers, S, Maertens, J, Pinczés, LI, Hoenigl, M, Drgoňa, Ľ, Cuccaro, A, Bilgin, YM, Aujayeb, A, Rahimli, L, Gräfe, S, Sciumè, M, Mladenović, M, Çolak, GM, Sacchi, MV, Nordlander, A, Berg Venemyr, C, Hanáková, M, García-Poutón, N, Emarah, Z, Zambrotta, GPM, Nunes Rodrigues, R, Cordoba, R, Méndez, GA, Biernat, MM, Cornely, OA & Pagano, L 2022, '
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey',
Cancers, vol. 14, no. 22, 5530.
https://doi.org/10.3390/cancers14225530APA
Cattaneo, C., Salmanton-García, J., Marchesi, F., El-Ashwah, S., Itri, F., Weinbergerová, B., Gomes Da Silva, M., Dargenio, M., Dávila-Valls, J., Martín-Pérez, S., Farina, F., Van Doesum, J., Valković, T., Besson, C.
, Poulsen, C. B., López-García, A., Žák, P., Schönlein, M., Piukovics, K., ... Pagano, L. (2022).
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey.
Cancers,
14(22), [5530].
https://doi.org/10.3390/cancers14225530Vancouver
Cattaneo C, Salmanton-García J, Marchesi F, El-Ashwah S, Itri F, Weinbergerová B et al.
Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey.
Cancers. 2022;14(22). 5530.
https://doi.org/10.3390/cancers14225530Author
Cattaneo, Chiara ; Salmanton-García, Jon ; Marchesi, Francesco ; El-Ashwah, Shaimaa ; Itri, Federico ; Weinbergerová, Barbora ; Gomes Da Silva, Maria ; Dargenio, Michelina ; Dávila-Valls, Julio ; Martín-Pérez, Sonia ; Farina, Francesca ; Van Doesum, Jaap ; Valković, Toni ; Besson, Caroline ; Poulsen, Christian Bjørn ; López-García, Alberto ; Žák, Pavel ; Schönlein, Martin ; Piukovics, Klára ; Jaksic, Ozren ; Cabirta, Alba ; Ali, Natasha ; Sili, Uluhan ; Fracchiolla, Nicola ; Dragonetti, Giulia ; Adžić-Vukičević, Tatjana ; Marchetti, Monia ; Machado, Marina ; Glenthøj, Andreas ; Finizio, Olimpia ; Demirkan, Fatih ; Blennow, Ola ; Tisi, Maria Chiara ; Omrani, Ali S. ; Navrátil, Milan ; Ráčil, Zdeněk ; Novák, Jan ; Magliano, Gabriele ; Jiménez, Moraima ; Garcia-Vidal, Carolina ; Erben, Nurettin ; Del Principe, Maria Ilaria ; Buquicchio, Caterina ; Bergantim, Rui ; Batinić, Josip ; Al-Khabori, Murtadha ; Verga, Luisa ; Szotkowski, Tomáš ; Samarkos, Michail ; Ormazabal-Vélez, Irati ; Meers, Stef ; Maertens, Johan ; Pinczés, László Imre ; Hoenigl, Martin ; Drgoňa, Ľuboš ; Cuccaro, Annarosa ; Bilgin, Yavuz M. ; Aujayeb, Avinash ; Rahimli, Laman ; Gräfe, Stefanie ; Sciumè, Mariarita ; Mladenović, Miloš ; Çolak, Gökçe Melis ; Sacchi, Maria Vittoria ; Nordlander, Anna ; Berg Venemyr, Caroline ; Hanáková, Michaela ; García-Poutón, Nicole ; Emarah, Ziad ; Zambrotta, Giovanni Paolo Maria ; Nunes Rodrigues, Raquel ; Cordoba, Raul ; Méndez, Gustavo Adolfo ; Biernat, Monika M. ; Cornely, Oliver A. ; Pagano, Livio. / Simultaneous Onset of Haematological Malignancy and COVID : An Epicovideha Survey. In: Cancers. 2022 ; Vol. 14, No. 22.
Bibtex
@article{d7062d6fd5114b73a2ce5f07c74b4f8e,
title = "Simultaneous Onset of Haematological Malignancy and COVID: An Epicovideha Survey",
abstract = "Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.",
keywords = "COVID-19, haematological malignancy onset, outcome, prognostic factors, treatment",
author = "Chiara Cattaneo and Jon Salmanton-Garc{\'i}a and Francesco Marchesi and Shaimaa El-Ashwah and Federico Itri and Barbora Weinbergerov{\'a} and {Gomes Da Silva}, Maria and Michelina Dargenio and Julio D{\'a}vila-Valls and Sonia Mart{\'i}n-P{\'e}rez and Francesca Farina and {Van Doesum}, Jaap and Toni Valkovi{\'c} and Caroline Besson and Poulsen, {Christian Bj{\o}rn} and Alberto L{\'o}pez-Garc{\'i}a and Pavel {\v Z}{\'a}k and Martin Sch{\"o}nlein and Kl{\'a}ra Piukovics and Ozren Jaksic and Alba Cabirta and Natasha Ali and Uluhan Sili and Nicola Fracchiolla and Giulia Dragonetti and Tatjana Ad{\v z}i{\'c}-Vuki{\v c}evi{\'c} and Monia Marchetti and Marina Machado and Andreas Glenth{\o}j and Olimpia Finizio and Fatih Demirkan and Ola Blennow and Tisi, {Maria Chiara} and Omrani, {Ali S.} and Milan Navr{\'a}til and Zden{\v e}k R{\'a}{\v c}il and Jan Nov{\'a}k and Gabriele Magliano and Moraima Jim{\'e}nez and Carolina Garcia-Vidal and Nurettin Erben and {Del Principe}, {Maria Ilaria} and Caterina Buquicchio and Rui Bergantim and Josip Batini{\'c} and Murtadha Al-Khabori and Luisa Verga and Tom{\'a}{\v s} Szotkowski and Michail Samarkos and Irati Ormazabal-V{\'e}lez and Stef Meers and Johan Maertens and Pincz{\'e}s, {L{\'a}szl{\'o} Imre} and Martin Hoenigl and {\v L}ubo{\v s} Drgo{\v n}a and Annarosa Cuccaro and Bilgin, {Yavuz M.} and Avinash Aujayeb and Laman Rahimli and Stefanie Gr{\"a}fe and Mariarita Scium{\`e} and Milo{\v s} Mladenovi{\'c} and {\c C}olak, {G{\"o}k{\c c}e Melis} and Sacchi, {Maria Vittoria} and Anna Nordlander and {Berg Venemyr}, Caroline and Michaela Han{\'a}kov{\'a} and Nicole Garc{\'i}a-Pout{\'o}n and Ziad Emarah and Zambrotta, {Giovanni Paolo Maria} and {Nunes Rodrigues}, Raquel and Raul Cordoba and M{\'e}ndez, {Gustavo Adolfo} and Biernat, {Monika M.} and Cornely, {Oliver A.} and Livio Pagano",
note = "Publisher Copyright: {\textcopyright} 2022 by the authors.",
year = "2022",
doi = "10.3390/cancers14225530",
language = "English",
volume = "14",
journal = "Cancers",
issn = "2072-6694",
publisher = "M D P I AG",
number = "22",
}
RIS
TY - JOUR
T1 - Simultaneous Onset of Haematological Malignancy and COVID
T2 - An Epicovideha Survey
AU - Cattaneo, Chiara
AU - Salmanton-García, Jon
AU - Marchesi, Francesco
AU - El-Ashwah, Shaimaa
AU - Itri, Federico
AU - Weinbergerová, Barbora
AU - Gomes Da Silva, Maria
AU - Dargenio, Michelina
AU - Dávila-Valls, Julio
AU - Martín-Pérez, Sonia
AU - Farina, Francesca
AU - Van Doesum, Jaap
AU - Valković, Toni
AU - Besson, Caroline
AU - Poulsen, Christian Bjørn
AU - López-García, Alberto
AU - Žák, Pavel
AU - Schönlein, Martin
AU - Piukovics, Klára
AU - Jaksic, Ozren
AU - Cabirta, Alba
AU - Ali, Natasha
AU - Sili, Uluhan
AU - Fracchiolla, Nicola
AU - Dragonetti, Giulia
AU - Adžić-Vukičević, Tatjana
AU - Marchetti, Monia
AU - Machado, Marina
AU - Glenthøj, Andreas
AU - Finizio, Olimpia
AU - Demirkan, Fatih
AU - Blennow, Ola
AU - Tisi, Maria Chiara
AU - Omrani, Ali S.
AU - Navrátil, Milan
AU - Ráčil, Zdeněk
AU - Novák, Jan
AU - Magliano, Gabriele
AU - Jiménez, Moraima
AU - Garcia-Vidal, Carolina
AU - Erben, Nurettin
AU - Del Principe, Maria Ilaria
AU - Buquicchio, Caterina
AU - Bergantim, Rui
AU - Batinić, Josip
AU - Al-Khabori, Murtadha
AU - Verga, Luisa
AU - Szotkowski, Tomáš
AU - Samarkos, Michail
AU - Ormazabal-Vélez, Irati
AU - Meers, Stef
AU - Maertens, Johan
AU - Pinczés, László Imre
AU - Hoenigl, Martin
AU - Drgoňa, Ľuboš
AU - Cuccaro, Annarosa
AU - Bilgin, Yavuz M.
AU - Aujayeb, Avinash
AU - Rahimli, Laman
AU - Gräfe, Stefanie
AU - Sciumè, Mariarita
AU - Mladenović, Miloš
AU - Çolak, Gökçe Melis
AU - Sacchi, Maria Vittoria
AU - Nordlander, Anna
AU - Berg Venemyr, Caroline
AU - Hanáková, Michaela
AU - García-Poutón, Nicole
AU - Emarah, Ziad
AU - Zambrotta, Giovanni Paolo Maria
AU - Nunes Rodrigues, Raquel
AU - Cordoba, Raul
AU - Méndez, Gustavo Adolfo
AU - Biernat, Monika M.
AU - Cornely, Oliver A.
AU - Pagano, Livio
N1 - Publisher Copyright:
© 2022 by the authors.
PY - 2022
Y1 - 2022
N2 - Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.
AB - Background: The outcome of patients with simultaneous diagnosis of haematological malignancies (HM) and COVID-19 is unknown and there are no specific treatment guidelines. Methods: We describe the clinical features and outcome of a cohort of 450 patients with simultaneous diagnosis of HM and COVID-19 registered in the EPICOVIDEHA registry between March 2020 to February 2022. Results: Acute leukaemia and lymphoma were the most frequent HM (35.8% and 35.1%, respectively). Overall, 343 (76.2%) patients received treatment for HM, which was delayed for longer than one month since diagnosis in 57 (16.6%). An overall response rate was observed in 140 (40.8%) patients after the first line of treatment. After a median follow-up of 35 days, overall mortality was 177/450 (39.3%); 30-day mortality was significantly higher in patients not receiving HM treatment (42.1%) than in those receiving treatment (27.4%, p = 0.004), either before and/or after COVID-19, or compared to patients receiving HM treatment at least after COVID-19 (15.2%, p < 0.001). Age, severe/critical COVID-19, ≥2 comorbidities, and lack of HM treatment were independent risk factors for mortality, whereas a lymphocyte count >500/mcl at COVID-19 onset was protective. Conclusions: HM treatment should be delivered as soon as possible for patients with simultaneous diagnosis of COVID-19 and HM requiring immediate therapy.
KW - COVID-19
KW - haematological malignancy onset
KW - outcome
KW - prognostic factors
KW - treatment
U2 - 10.3390/cancers14225530
DO - 10.3390/cancers14225530
M3 - Journal article
C2 - 36428621
AN - SCOPUS:85142475288
VL - 14
JO - Cancers
JF - Cancers
SN - 2072-6694
IS - 22
M1 - 5530
ER -
